Literature DB >> 8471144

Plasma tumour necrosis factor-alpha (TNF-alpha) levels in patients with burns.

S Endo1, K Inada, Y Yamada, T Kasai, T Takakuwa, H Nakae, M Kikuchi, S Hoshi, M Suzuki, H Yamashita.   

Abstract

Levels of plasma tumour necrosis factor-alpha (TNF-alpha) were determined consecutively in 42 patients with burns > 20 per cent of the total body surface area using an enzyme-linked immunosorbent assay. In the early period after injury (including the period of burn shock), 24 patients had detectable TNF-alpha levels in their plasma. However, the plasma TNF-alpha levels at the time of admission were very low and did not correlate with the extent of the burn or the prognosis. In contrast, the maximum plasma TNF-alpha level over the whole clinical course was significantly correlated with the area of the burn and the prognosis. No correlation was found between the plasma TNF-alpha and plasma endotoxin levels. TNF-alpha may be produced locally in infected burns and monitoring of plasma TNF-alpha levels may be a useful prognostic indicator for burns patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8471144     DOI: 10.1016/0305-4179(93)90033-5

Source DB:  PubMed          Journal:  Burns        ISSN: 0305-4179            Impact factor:   2.744


  11 in total

Review 1.  Novel pharmacotherapy for burn wounds: what are the advancements.

Authors:  Michael R Hamblin
Journal:  Expert Opin Pharmacother       Date:  2018-12-05       Impact factor: 3.889

2.  Suppressive effects of sivelestat on interleukin 8 and TNF-α production from LPS-stimulated granulocytes in whole blood culture.

Authors:  Shigehiro Shibata; Gaku Takahashi; Nobuki Shioya; Katsuya Inada; Shigeatsu Endo
Journal:  J Anesth       Date:  2010-10-26       Impact factor: 2.078

3.  Burn-associated delayed dilated cardiomyopathy evaluated by cardiac PET and SPECT: Report of a case.

Authors:  Reimu Fukui; Hideaki Suzuki; Noriko Miyagawa; Tomoyuki Endo; Tomohiro Kaneta; Koichiro Sugimura; Yasuharu Matsumoto; Shoki Takahashi; Yutaka Kagaya; Shigeki Kushimoto; Hiroaki Shimokawa
Journal:  J Cardiol Cases       Date:  2014-08-10

4.  Innate immunity SNPs are associated with risk for severe sepsis after burn injury.

Authors:  Robert C Barber; Ling-Yu E Chang; Brett D Arnoldo; Gary F Purdue; John L Hunt; Jureta W Horton; Corinne C Aragaki
Journal:  Clin Med Res       Date:  2006-12

5.  The effects of the early administration of sivelestat sodium, a selective neutrophil elastase inhibitor, on the postoperative course after radical surgery for esophageal cancer.

Authors:  Junichi Nishiyama; Mitsumasa Matsuda; Satoko Ando; Miyoko Hirasawa; Toshiyasu Suzuki; Hiroyasu Makuuchi
Journal:  Surg Today       Date:  2011-12-27       Impact factor: 2.549

6.  TLR4 and TNF-alpha polymorphisms are associated with an increased risk for severe sepsis following burn injury.

Authors:  R C Barber; C C Aragaki; F A Rivera-Chavez; G F Purdue; J L Hunt; J W Horton
Journal:  J Med Genet       Date:  2004-11       Impact factor: 6.318

7.  The effective removal of proinflammatory cytokines by continuous hemofiltration with a polymethylmethacrylate membrane following severe burn injury: report of three cases.

Authors:  H Nakae; S Motoyama; S Kurosawa; H Inaba
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

8.  Investigation of the cause of readmission to the intensive care unit for patients with lung edema or atelectasis.

Authors:  Yoshinori Matsuoka; Akinori Zaitsu; Makoto Hashizume
Journal:  Yonsei Med J       Date:  2008-06-30       Impact factor: 2.759

9.  Characterization of the inflammatory response during acute and post-acute phases after severe burn.

Authors:  Gerd G Gauglitz; Juquan Song; David N Herndon; Celeste C Finnerty; Darren Boehning; José M Barral; Marc G Jeschke
Journal:  Shock       Date:  2008-11       Impact factor: 3.454

10.  Serum IL-18 is increased at early postburn period in moderately burned patients.

Authors:  Y Kenan Coban; Murat Aral
Journal:  Mediators Inflamm       Date:  2006       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.